GBT Stock: Why Pfizer's $5.4 Billion Takeover Is 'Mutually Beneficial' | Investor's Business Daily - Investor's Business Daily

The deal adds to Pfizer's efforts to tackle sickle cell disease.

Drug giant Pfizer (PFE) inked a $5.4 billion deal Monday to buy Global Blood Therapeutics (GBT), confirming rumors that sent GBT stock skyrocketing last week. XThe deal could add a peak $3 billion i… [+3278 chars]

full article...